Skip to main content

Advertisement

SpringerLink
Log in

Helicobacter pylori: Evidence-Based Review with a Focus on Immigrant Populations

  • Review
  • Published:
Journal of General Internal Medicine Aims and scope Submit manuscript

Abstract

Helicobacter pylori has been causally linked to a number of diseases, including peptic ulcer disease, gastric adenocarcinoma, mucosa-associated lymphoid tissue lymphoma, and dyspepsia. It is the most prevalent bacterial pathogen in humans, and while the overall prevalence in the United States is about 30 %, the distribution is heterogeneous amongst different ethnic groups. Recent immigrants from high prevalence areas such as Korea, Japan, and China bear an increased burden of its disease and complications. There is clear evidence that treatment of H. pylori resolves peptic ulcer disease, and increasing evidence for protection against development of gastric adenocarcinoma. However, H. pylori treatment failure is common and alternative regimens may be necessary. The following case-based review will highlight these issues, including the epidemiology of H. pylori in the immigrant population, an approach to dyspepsia, and the role of H. pylori in gastric adenocarcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

REFERENCES

  1. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1(8390):1311–5.

    Article  CAS  PubMed  Google Scholar 

  2. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345(11):784–9. doi:10.1056/NEJMoa001999.

    Article  CAS  PubMed  Google Scholar 

  3. Watanabe T, Tada M, Nagai H, Sasaki S, Nakao M. Helicobacter pylori infection induces gastric cancer in mongolian gerbils. Gastroenterology. 1998;115(3):642–8.

    Article  CAS  PubMed  Google Scholar 

  4. Wotherspoon AC, Diss TC, Pan LX, Schmid C, Kerr-Muir MG, Lea SH, et al. Primary low-grade B-cell lymphoma of the conjunctiva: a mucosa-associated lymphoid tissue type lymphoma. Histopathology. 1993;23(5):417–24.

    Article  CAS  PubMed  Google Scholar 

  5. DuBois S, Kearney DJ. Iron-deficiency anemia and Helicobacter pylori infection: a review of the evidence. Am J Gastroenterol. 2005;100(2):453–9. doi:10.1111/j.1572-0241.2005.30252.x.

    Article  PubMed  Google Scholar 

  6. Emilia G, Luppi M, Zucchini P, Morselli M, Potenza L, Forghieri F, et al. Helicobacter pylori infection and chronic immune thrombocytopenic purpura: long-term results of bacterium eradication and association with bacterium virulence profiles. Blood. 2007;110(12):3833–41. doi:10.1182/blood-2006-12-063222.

    Article  CAS  PubMed  Google Scholar 

  7. Raghunath A, Hungin AP, Wooff D, Childs S. Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review. BMJ. 2003;326(7392):737. doi:10.1136/bmj.326.7392.737.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Moayyedi P, Deeks J, Talley NJ, Delaney B, Forman D. An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. Am J Gastroenterol. 2003;98(12):2621–6. doi:10.1111/j.1572-0241.2003.08724.x.

    Article  PubMed  Google Scholar 

  9. Pounder RE, Ng D. The prevalence of Helicobacter pylori infection in different countries. Aliment Pharmacol Ther. 1995;9(Suppl 2):33–9.

    PubMed  Google Scholar 

  10. Everhart JE. Recent developments in the epidemiology of Helicobacter pylori. Gastroenterol Clin N Am. 2000;29(3):559–78.

    Article  CAS  Google Scholar 

  11. Grad YH, Lipsitch M, Aiello AE. Secular trends in Helicobacter pylori seroprevalence in adults in the United States: evidence for sustained race/ethnic disparities. Am J Epidemiol. 2012;175(1):54–9. doi:10.1093/aje/kwr288.

    Article  PubMed Central  PubMed  Google Scholar 

  12. Yeh JM, Hur C, Schrag D, Kuntz KM, Ezzati M, Stout N, et al. Contribution of H. pylori and smoking trends to US incidence of intestinal-type noncardia gastric adenocarcinoma: a microsimulation model. PLoS Med. 2013;10(5):e1001451.

    Article  PubMed Central  PubMed  Google Scholar 

  13. Fock KM, Ang TL. Epidemiology of Helicobacter pylori infection and gastric cancer in Asia. J Gastroenterol Hepatol. 2010;25(3):479–86. doi:10.1111/j.1440-1746.2009.06188.x.

    Article  CAS  PubMed  Google Scholar 

  14. Tsai CJ, Perry S, Sanchez L, Parsonnet J. Helicobacter pylori infection in different generations of Hispanics in the San Francisco Bay Area. Am J Epidemiol. 2005;162(4):351–7. doi:10.1093/aje/kwi207.

    Article  PubMed  Google Scholar 

  15. Talley NJ.American Gastroenterological Association medical position statement: evaluation of dyspepsia. Gastroenterology. 2005;129(5):1753–5. doi:10.1053/j.gastro.2005.09.019.

    Article  PubMed  Google Scholar 

  16. Hansen JM, Bytzer P.Value of the unaided clinical diagnosis in dyspeptic patients in primary care. Am J Gastroenterol. 2001;96(5):1417–21.

  17. Hammer J, Eslick GD, Howell SC, Altiparmak E, Talley NJ. Diagnostic yield of alarm features in irritable bowel syndrome and functional dyspepsia. Gut. 2004;53(5):666–72.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Heikkinen M, Pikkarainen P, Takala J, Rasanen H, Julkunen R. Etiology of dyspepsia: four hundred unselected consecutive patients in general practice. Scand J Gastroenterol. 1995;30(6):519–23.

    Article  CAS  PubMed  Google Scholar 

  19. Chiba N, Van Zanten SJ, Sinclair P, Ferguson RA, Escobedo S, Grace E. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial. BMJ (Clin Res ed). 2002;324(7344):1012–6.

    Article  CAS  Google Scholar 

  20. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002;359(9300):14–22. doi:10.1016/S0140-6736(02)07273-2.

    Article  CAS  PubMed  Google Scholar 

  21. Leodolter A, Kulig M, Brasch H, Meyer-Sabellek W, Willich SN, Malfertheiner P. A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther. 2001;15(12):1949–58.

    Article  CAS  PubMed  Google Scholar 

  22. Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, et al. Management of Helicobacter pylori infection--the Maastricht IV/Florence Consensus Report. Gut. 2012;61(5):646–64. doi:10.1136/gutjnl-2012-302084.

    Article  CAS  PubMed  Google Scholar 

  23. Chan FK, Ching JY, Suen BY, Tse YK, Wu JC, Sung JJ. Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users. Gastroenterology. 2013;144(3):528–35. doi:10.1053/j.gastro.2012.12.038.

    Article  CAS  PubMed  Google Scholar 

  24. Loy CT, Irwig LM, Katelaris PH, Talley NJ. Do commercial serological kits for Helicobacter pylori infection differ in accuracy? A meta-analysis. Am J Gastroenterol. 1996;91(6):1138–44.

    CAS  PubMed  Google Scholar 

  25. Nurgalieva ZZ, Graham DY. Pearls and pitfalls of assessing Helicobacter pylori status. Dig Liver Dis. 2003;35(6):375–7.

    Article  CAS  PubMed  Google Scholar 

  26. Chey WD. Accurate diagnosis of Helicobacter pylori. 14C-urea breath test. Gastroenterol Clin N Am. 2000;29(4):895–902.

    Article  CAS  Google Scholar 

  27. Peura DA, Pambianco DJ, Dye KR, Lind C, Frierson HF, Hoffman SR, et al. Microdose 14C-urea breath test offers diagnosis of Helicobacter pylori in 10 minutes. Am J Gastroenterol. 1996;91(2):233–8.

    CAS  PubMed  Google Scholar 

  28. Chey WD, Wong BC. Practice parameters committee of the American College of G. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007;102(8):1808–25. doi:10.1111/j.1572-0241.2007.01393.x.

    Article  CAS  PubMed  Google Scholar 

  29. Chey WD, Woods M, Scheiman JM, Nostrant TT, DelValle J. Lansoprazole and ranitidine affect the accuracy of the 14C-urea breath test by a pH-dependent mechanism. Am J Gastroenterol. 1997;92(3):446–50.

    CAS  PubMed  Google Scholar 

  30. Stermer E, Levy N, Tabak M, Neeman I. Lanzoprazole and ranitidine affect the accuracy of the 14C-urea breath test by a pH-dependent mechanism. Am J Gastroenterol. 1997;92(9):1575–6.

    CAS  PubMed  Google Scholar 

  31. Gisbert JP, Pajares JM. Stool antigen test for the diagnosis of Helicobacter pylori infection: a systematic review. Helicobacter. 2004;9(4):347–68. doi:10.1111/j.1083-4389.2004.00235.x.

    Article  PubMed  Google Scholar 

  32. Bravo LE, Realpe JL, Campo C, Mera R, Correa P. Effects of acid suppression and bismuth medications on the performance of diagnostic tests for Helicobacter pylori infection. Am J Gastroenterol. 1999;94(9):2380–3. doi:10.1111/j.1572-0241.1999.01361.x.

    Article  CAS  PubMed  Google Scholar 

  33. Hansen S, Melby KK, Aase S, Jellum E, Vollset SE. Helicobacter pylori infection and risk of cardia cancer and non-cardia gastric cancer. A nested case–control study. Scand J Gastroenterol. 1999;34(4):353–60.

    Article  CAS  PubMed  Google Scholar 

  34. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991;325(16):1127–31. doi:10.1056/NEJM199110173251603.

    Article  CAS  PubMed  Google Scholar 

  35. International Agency for Research on Cancer. Schistosomes, liver flukes and Helicobacter pylori. IARC working group on the evaluation of carcinogenic risks to humans. Lyon, 7–14 June 1994. IARC monographs on the evaluation of carcinogenic risks to humans/World Health Organization, International Agency for Research on Cancer. 1994;61:1–241.

  36. Brenner H, Arndt V, Stegmaier C, Ziegler H, Rothenbacher D. Is Helicobacter pylori infection a necessary condition for noncardia gastric cancer? Am J Epidemiol. 2004;159(3):252–8.

    Article  PubMed  Google Scholar 

  37. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process–First American cancer society award lecture on cancer epidemiology and prevention. Cancer Res. 1992;52(24):6735–40.

    CAS  PubMed  Google Scholar 

  38. Kuipers EJ, Uyterlinde AM, Pena AS, Roosendaal R, Pals G, Nelis GF, et al. Long-term sequelae of Helicobacter pylori gastritis. Lancet. 1995;345(8964):1525–8.

    Article  CAS  PubMed  Google Scholar 

  39. Yakirevich E, Resnick MB. Pathology of gastric cancer and its precursor lesions. Gastroenterol Clin North Am. 2013;42(2):261–84. doi:10.1016/j.gtc.2013.01.004.

    Article  PubMed  Google Scholar 

  40. Fox JG, Wang TC. Inflammation, atrophy, and gastric cancer. J Clin Investigat. 2007;117(1):60–9. doi:10.1172/JCI30111.

    Article  CAS  Google Scholar 

  41. El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature. 2000;404(6776):398–402. doi:10.1038/35006081.

    Article  CAS  PubMed  Google Scholar 

  42. El-Omar EM, Oien K, Murray LS, El-Nujumi A, Wirz A, Gillen D, et al. Increased prevalence of precancerous changes in relatives of gastric cancer patients: critical role of H. pylori. Gastroenterology. 2000;118(1):22–30.

    Article  CAS  PubMed  Google Scholar 

  43. Joossens JV, Hill MJ, Elliott P, Stamler R, Lesaffre E, Dyer A, et al. Dietary salt, nitrate and stomach cancer mortality in 24 countries. European Cancer Prevention (ECP) and the INTERSALT Cooperative Research Group. Int J Epidemiol. 1996;25(3):494–504.

    Article  CAS  PubMed  Google Scholar 

  44. Chen MJ, Wu DC, Ko YC, Chiou YY. Personal history and family history as a predictor of gastric cardiac adenocarcinoma risk: a case–control study in Taiwan. Am J Gastroenterol. 2004;99(7):1250–7. doi:10.1111/j.1572-0241.2004.30872.x.

    Article  PubMed  Google Scholar 

  45. Lau M, Le A, El-Serag HB. Noncardia gastric adenocarcinoma remains an important and deadly cancer in the United States: secular trends in incidence and survival. Am J Gastroenterol. 2006;101(11):2485–92. doi:10.1111/j.1572-0241.2006.00778.x.

    Article  PubMed  Google Scholar 

  46. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer. J Int du Cancer. 2010;127(12):2893–917. doi:10.1002/ijc.25516.

    Article  CAS  Google Scholar 

  47. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.

    Article  PubMed  Google Scholar 

  48. Talley NJ, Fock KM, Moayyedi P. Gastric Cancer Consensus conference recommends Helicobacter pylori screening and treatment in asymptomatic persons from high-risk populations to prevent gastric cancer. Am J Gastroenterol. 2008;103(3):510–4. doi:10.1111/j.1572-0241.2008.01819.x.

    Article  PubMed  Google Scholar 

  49. Howe HL, Wu X, Ries LA, Cokkinides V, Ahmed F, Jemal A, et al. Annual report to the nation on the status of cancer, 1975–2003, featuring cancer among U.S. Hispanic/Latino populations. Cancer. 2006;107(8):1711–42.

    Article  PubMed  Google Scholar 

  50. Hirota WK, Zuckerman MJ, Adler DG, Davila RE, Egan J, Leighton JA, et al. ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc. 2006;63(4):570–80. doi:10.1016/j.gie.2006.02.004.

    Article  PubMed  Google Scholar 

  51. Uemura N, Mukai T, Okamoto S, Yamaguchi S, Mashiba H, Taniyama K, et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomark Prev. 1997;6(8):639–42.

    CAS  Google Scholar 

  52. Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008;372(9636):392–7. doi:10.1016/S0140-6736(08)61159-9.

    Article  PubMed  Google Scholar 

  53. Kato M, Asaka M. Recent knowledge of the relationship between Helicobacter pylori and gastric cancer and recent progress of gastroendoscopic diagnosis and treatment for gastric cancer. Jpn J Clin Oncol. 2010;40(9):828–37. doi:10.1093/jjco/hyq119.

    Article  PubMed  Google Scholar 

  54. Rokkas T, Sechopoulos P, Robotis I, Margantinis G, Pistiolas D. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. Am J Gastroenterol. 2009;104(1):21–5. doi:10.1038/ajg.2008.87.

    Article  CAS  PubMed  Google Scholar 

  55. Zhou L, Sung JJ, Lin S, Jin Z, Ding S, Huang X, et al. A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication. Chin Med J. 2003;116(1):11–4.

    PubMed  Google Scholar 

  56. Fuccio L, Zagari RM, Eusebi LH, Laterza L, Cennamo V, Ceroni L, et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med. 2009;151(2):121–8.

    Article  PubMed  Google Scholar 

  57. Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, et al. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol. 2009;24(10):1587–600. doi:10.1111/j.1440-1746.2009.05982.x.

    Article  PubMed  Google Scholar 

  58. Fock KM, Talley N, Moayyedi P, Hunt R, Azuma T, Sugano K, et al. Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol. 2008;23(3):351–65. doi:10.1111/j.1440-1746.2008.05314.x.

    Article  PubMed  Google Scholar 

  59. Malfertheiner P, Sipponen P, Naumann M, Moayyedi P, Megraud F, Xiao SD, et al. Helicobacter pylori eradication has the potential to prevent gastric cancer: a state-of-the-art critique. Am J Gastroenterol. 2005;100(9):2100–15. doi:10.1111/j.1572-0241.2005.41688.x.

    Article  PubMed  Google Scholar 

  60. Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter. 2007;12(4):275–8. doi:10.1111/j.1523-5378.2007.00518.x.

    Article  PubMed  Google Scholar 

  61. Katelaris PH, Forbes GM, Talley NJ, Crotty B. A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study. Gastroenterology. 2002;123(6):1763–9. doi:10.1053/gast.2002.37051.

    Article  PubMed  Google Scholar 

  62. Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol. 2010;105(1):65–73. doi:10.1038/ajg.2009.508.

    Article  PubMed  Google Scholar 

  63. Gene E, Calvet X, Azagra R, Gisbert JP. Triple vs quadruple therapy for treating Helicobacter pylori infection: an updated meta-analysis. Aliment Pharmacol Ther. 2003;18(5):543–4.

    Article  CAS  PubMed  Google Scholar 

  64. Osato MS, Reddy R, Reddy SG, Penland RL, Malaty HM, Graham DY. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch Intern Med. 2001;161(9):1217–20.

    Article  CAS  PubMed  Google Scholar 

  65. McMahon BJ, Hennessy TW, Bensler JM, Bruden DL, Parkinson AJ, Morris JM, et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med. 2003;139(6):463–9.

    Article  PubMed  Google Scholar 

  66. Fischbach LA, Goodman KJ, Feldman M, Aragaki C. Sources of variation of Helicobacter pylori treatment success in adults worldwide: a meta-analysis. Int J Epidemiol. 2002;31(1):128–39.

    Article  PubMed  Google Scholar 

  67. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59(8):1143–53. doi:10.1136/gut.2009.192757.

    Article  CAS  PubMed  Google Scholar 

  68. Vaira D, Zullo A, Vakil N, Gatta L, Ricci C, Perna F, et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med. 2007;146(8):556–63.

    Article  PubMed  Google Scholar 

  69. Liou JM, Chen CC, Chen MJ, Chen CC, Chang CY, Fang YJ, et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet. 2013;381(9862):205–13. doi:10.1016/S0140-6736(12)61579-7.

    Article  PubMed  Google Scholar 

  70. Hojo M, Miwa H, Nagahara A, Sato N. Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand J Gastroenterol. 2001;36(7):690–700.

    Article  CAS  PubMed  Google Scholar 

  71. Gisbert JP, Gisbert JL, Marcos S, Jimenez-Alonso I, Moreno-Otero R, Pajares JM. Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients. Aliment Pharmacol Ther. 2008;27(4):346–54. doi:10.1111/j.1365-2036.2007.03573.x.

    Article  CAS  PubMed  Google Scholar 

  72. Basu PP, Rayapudi K, Pacana T, Shah NJ, Krishnaswamy N, Flynn M. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am J Gastroenterol. 2011;106(11):1970–5.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  73. Romano M, Cuomo A, Gravina AG, Miranda A, Iovene MR, Tiso A, et al. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut. 2010;59(11):1465–70. doi:10.1136/gut.2010.215350.

    Article  CAS  PubMed  Google Scholar 

  74. Saad RJ, Schoenfeld P, Kim HM, Chey WD. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol. 2006;101(3):488–96. doi:10.1111/j.1572-0241.1998.455_t.x.

    Article  CAS  PubMed  Google Scholar 

  75. Tay CY, Windsor HM, Thirriot F, Lu W, Conway C, Perkins TT, et al. Helicobacter pylori eradication in Western Australia using novel quadruple therapy combinations. Aliment Pharmacol Ther. 2012;36(11–12):1076–83. doi:10.1111/apt.12089.

    Article  CAS  PubMed  Google Scholar 

  76. Yun SP, Seon HG, Ok CS, Yoo KH, Kang MK, Kim WH, et al. Rifaximin plus levofloxacin-based rescue regimen for the eradication of Helicobacter pylori. Gut Liver. 2012;6(4):452–6. doi:10.5009/gnl.2012.6.4.452.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  77. Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology. 1996;110(4):1244–52.

    Article  CAS  PubMed  Google Scholar 

  78. Lee M, Kemp JA, Canning A, Egan C, Tataronis G, Farraye FA. A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori therapy. Arch Intern Med. 1999;159(19):2312–6.

    Article  CAS  PubMed  Google Scholar 

  79. Graham DY, Lew GM, Malaty HM, Evans DG, Evans DJ Jr, Klein PD, et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology. 1992;102(2):493–6.

    CAS  PubMed  Google Scholar 

  80. Morgan DR, Torres J, Sexton R, Herrero R, Salazar-Martinez E, Greenberg ER, et al. Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities. JAMA. 2013;309(6):578–86. doi:10.1001/jama.2013.311.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  81. Sonnenberg A, Everhart JE. Health impact of peptic ulcer in the United States. Am J Gastroenterol. 1997;92(4):614–20.

    CAS  PubMed  Google Scholar 

  82. Sonnenberg A, Schwartz JS, Cutler AF, Vakil N, Bloom BS. Cost savings in duodenal ulcer therapy through Helicobacter pylori eradication compared with conventional therapies: results of a randomized, double-blind, multicenter trial. Gastrointestinal Utilization Trial Study Group. Arch Intern Med. 1998;158(8):852–60.

    Article  CAS  PubMed  Google Scholar 

  83. Mapel D, Roberts M, Overhiser A, Mason A. The epidemiology, diagnosis, and cost of dyspepsia and Helicobacter pylori gastritis: a case–control analysis in the Southwestern United States. Helicobacter. 2013;18(1):54–65. doi:10.1111/j.1523-5378.2012.00988.x.

    Article  PubMed Central  PubMed  Google Scholar 

  84. Mason J, Axon AT, Forman D, Duffett S, Drummond M, Crocombe W, et al. The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial. Aliment Pharmacol Ther. 2002;16(3):559–68.

    Article  CAS  PubMed  Google Scholar 

  85. Ford AC, Forman D, Bailey AG, Axon AT, Moayyedi P. A community screening program for Helicobacter pylori saves money: 10-year follow-up of a randomized controlled trial. Gastroenterology. 2005;129(6):1910–7. doi:10.1053/j.gastro.2005.09.016.

    Article  PubMed  Google Scholar 

  86. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part I: overall and upper gastrointestinal diseases. Gastroenterology. 2009;136(2):376–86. doi:10.1053/j.gastro.2008.12.015.

    Article  PubMed  Google Scholar 

  87. Areia M, Carvalho R, Cadime AT, Rocha Goncalves F, Dinis-Ribeiro M. Screening for gastric cancer and surveillance of premalignant lesions: a systematic review of cost-effectiveness studies. Helicobacter. 2013. doi:10.1111/hel.12050.

    PubMed  Google Scholar 

  88. Leivo T, Salomaa A, Kosunen TU, Tuominen R, Farkkila M, Linna M, et al. Cost-benefit analysis of Helicobacter pylori screening. Health policy. 2004;70(1):85–96. doi:10.1016/j.healthpol.2004.02.004.

    Article  CAS  PubMed  Google Scholar 

  89. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther. 2007;26(3):343–57. doi:10.1111/j.1365-2036.2007.03386.x.

    Article  CAS  PubMed  Google Scholar 

  90. Zullo A, De Francesco V, Hassan C, Morini S, Vaira D. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut. 2007;56(10):1353–7. doi:10.1136/gut.2007.125658.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the National Institutes of Health NCI K23 CA157929.

Conflict of Interest

The authors declare that they do not have a conflict of interest.

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Gastroenterology, University of California San Francisco, 513 Parnassus Ave., Rm-357, San Francisco, CA, 94143, USA

    Derrick Siao MD & Ma Somsouk MD, MAS

Authors
  1. Derrick Siao MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ma Somsouk MD, MAS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Derrick Siao MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Siao, D., Somsouk, M. Helicobacter pylori: Evidence-Based Review with a Focus on Immigrant Populations. J GEN INTERN MED 29, 520–528 (2014). https://doi.org/10.1007/s11606-013-2630-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11606-013-2630-y

KEY WORDS

Search

Navigation